Lancet Infectious Diseases

Article	Citations
Adaora “Ada” Alise Adimora	1515
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis	1227
Highlights from the sixth ESCMID Conference on Vaccines	1016
DNDi receives Dutch funding boost	567
HIV vaccine trial failure	549
Research in brief	481
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum	438
COVID-19 vaccination protects children and adolescents	414
A patient with secondary syphilis following incomplete treatment of primary infection	372
Environment and infectious diseases	365
Promoting diversity and equity in publishing	344
A step forward in the journey towards hookworm vaccines	306
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7	292
Listeria monocytogenes: a rare, deadly cause of peritonitis	285
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations	279
Updated criteria for paediatric sepsis and septic shock	277
Correction to Lancet Infect Dis 2025; 25: e280–93	265
Infectious disease surveillance update	257
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges	253
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation	252
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1	241
Surge of cutaneous leishmaniasis in Pakistan	240
Reflecting on lessons from the 2014–16 Ebola virus outbreak	238
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations	230
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis	224

Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco	224
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria	214
Measles immunity gaps and outbreak risk in a shifting landscape	213
The next chapter for Africa's genomic initiatives	205
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic	201
The lasting lessons of mpox: infection, vaccination, and immune memory	191
Attention to skin-related neglected tropical diseases	185
Shaping opportunities for future clinical trials in tuberculosis	182
Ivan Hirsch	181
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden	172
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting	172
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C	167
Threat of HIV and tuberculosis drug resistance after US funding cuts	166
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial	164
The superiority of bivalent over monovalent booster vaccines	163
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children	159
Dihydroartemisinin–piperaquine versus chloroquine for the treatment of uncomplicated Plasmodium vivax malaria with concurrent or delayed high-dose primaquine in Brazil (Curavivax): an open-label, sing	157
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect	157
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study	155
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study	152
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review	148
Kyasanur Forest disease: an emerging arboviral threat	146
Best practice guidelines for viral hepatitis service delivery in prisons	145
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial	145
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9–14 years compared with three doses of quadrivalent HPV vaccine in wom	145
Below-knee amputation following osteomyelitis from multidrug-resistant Stenotrophomonas maltophilia in a diabetic foot ulcer	143
GoGoVax dispels hopes for gonorrhoea vaccination	142
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial	141
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial	141
Mpox in people with past infection or a complete vaccination course: a global case series	140
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study	140
Research in brief	139
Research in brief	139
New flavours of tuberculosis treatment for children	138
We need estimates of gonorrhoea vaccine protection and symptomaticity by sex and anatomical site	137
Global cholera resurgence—a preventable tragedy	137
A new monoclonal in the arMAMentarium against malaria	137
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents	137
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia	136
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study	136
The implications of mpox breakthrough infections on future vaccination strategies	135
Theresa Ochoa—staying on top of infectious diseases in Peru	133
Research in brief	128
RSV prevention: public health lessons from the southern hemisphere	122
Full-dose NSAIDs at the first sign of respiratory infection?	121
Tuberculosis recovery in Georgia: implementing more by 24	121
Election of Regional Director for the Western Pacific	119
Emil Gotschlich	117
Supporting healthcare access for refugees and migrants	116
Interplay of infection and vaccination in long-term protection from COVID-19	114

Serpiginous-like choroiditis in ocular tuberculosis	114
Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world	114
Infectious disease surveillance update	113
Correction to Lancet Infect Dis 2026; published online March 23. https://doi.org/10.1016/S1473-3099(26)00058-7	113
Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86	111
COVID-19 mortality in Africa and Asia – Authors' reply	110
High-dose primaquine reduces vivax relapses: time for change	108
Elisabeth Presterl—always looking forward	107
Research in brief	105
The response of mpox-associated inflammatory syndrome to steroid therapy	105
Immune evasiveness of SARS-CoV-2 variants and vaccine selection	104
Guidelines adherence as a major protective aspect to increase survival rate in patients with candidaemia in Europe	102
Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study	101
Pre-emptively tackling vaccine misinformation for a successful large-scale roll-out of malaria vaccines in Africa	99
Addressing the shortage of cholera vaccines	99
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine	98
Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?	98
Twin threats: climate change and zoonoses	98
The global burden of cryptococcosis—a neglected tropical disease?	96
Curing chronic hepatitis B virus infection	95
Post-viral sequelae of COVID-19 and influenza	94
Evaluating H56:IC31 vaccine in tuberculosis recurrence prevention	94
Patient-centred approaches for drug-resistant tuberculosis	94
WHO publishes update on global antibiotic resistance	94
What can be learnt from the world's first national vaccination programme against gonorrhoea	92
Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance	90
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply	90
Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis	89
Correction to Lancet Infect Dis 2022; published online Aug 31. https://doi.org/10.1016/S1473-3099(22)00434-0	87
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2	86
Correction to Lancet Infect Dis 2023; 23: e469	86
Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-5	85
Correction to Lancet Infect Dis 2025; 25: e622	84
Correction to Lancet Infect Dis 2025; 25: e47–58	84
WHO Pathogen X conference	83
Malaria vaccine development in Mali: a step towards transmission-blocking strategies	83
Vaccine and surveillance implications of dengue underdetection	83
When mpox is not mpox: varicella and measles in DR Congo	82
First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis	82
Super-spreaders: a historical review	81
WHO's first global infection prevention and control report	80
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant	79
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-	79
Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis	79
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape	79
Spreading awareness on lymphatic filariasis	77
Imprinted hybrid immunity against XBB reinfection	77
Infectious disease surveillance update	77
A step closer to elimination of meningococcal disease	77
Lessons learnt from conducting a randomised clinical trial in eumycetoma	77
Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials	77
Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3	75
Gender and geographical representation at infectious diseases and clinical microbiology conferences	75
doxyPEP: a controversial new tool against STIs	75
Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluste	75
Pui-Ying Iroh Tam	72
Community-based mpox and sexually transmitted disease surveillance using discarded condoms in the global south	72
Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch	72
Correction to Lancet Infect Dis 2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00588-7	71
Correction to Lancet Infect Dis 2023; 23: e259–65	71
A tale of potential mpox reinfection	71
Correction to Lancet Infect Dis 2023; published online Aug 3. https://doi.org/10.1016/S1473-3099(23)00344-4	71
Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil	70
Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices	70
Vaccine pragmatism in the 21st century	70
On the frontline during the COVID-19 pandemic	70
Is the end of gonorrhoea in sight?	70
Amal Saif Al-Maani—fighting antimicrobial resistance	69
Highlights from ECCMID 2022	69
The urgent need to scale-up fungal diagnostics in Africa	69
Sir Michael Anthony Epstein	69
Moxidectin versus ivermectin for strongyloidiasis control	68
Child-friendly rifapentine formulation is a game changer	68
Social workers and neglected tropical diseases	68
Statistical concerns for meta-analysis of rare events and small sample sizes – Authors' reply	68
Advancing integration: progress reported for skin NTDs	67
Research in brief	67
RH5.1/Matrix-M: highlighting blood-stage malaria vaccines	67
Next-generation malaria subunit vaccines to reduce disease burden in African children	65
Human ocular thelaziosis—a zoonosis of the eye	65

Unexpected finding in a 17-year-old female undergoing screening colonoscopy	65
Sleeping sickness: time for dreaming	65
Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa	64
Effectiveness of pyriproxyfen-pyrethroid and chlorfenapyr-pyrethroid long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs for malaria control in the third year post-distribution:	64
DoxyPEP: thinking towards implementation	63
Bangladesh launches measles vaccine drive amid outbreak	63
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial	63
Efficacy of ETVAX, a vaccine against enterotoxigenic Escherichia coli-positive diarrhoea in Gambian children: a double-blind, randomised, placebo-controlled, phase 2b trial	63
Incidence and risk factors of tuberculosis among 420 854 household contacts of patients with tuberculosis in the 100 Million Brazilian Cohort (2004–18): a cohort study	63
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study	62
Re-emergence of Oropouche virus in Brazil and Latin America	61
COVID-19 mortality in Africa and Asia	61
A rare case of rabies-like Australian bat lyssavirus infection	60
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial	60
The spatiotemporal ecology of Oropouche virus across Latin America: a multidisciplinary, laboratory-based, modelling study	60
Prevention of non-ventilator-associated hospital-acquired pneumonia in Switzerland: a type 2 hybrid effectiveness–implementation trial	60
Lassa fever research priorities: towards effective medical countermeasures by the end of the decade	60
National case series of group A streptococcus pleural empyema in children: clinical and microbiological features	60
Outbreaks compound Brazil's flooding disaster	60
Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings	59
Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows	59
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster	58
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial	58
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis	58
Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study	58
Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study	58
Understanding the immunogenicity of RTS,S in infants	58
Randomised controlled trials for mpox in endemic countries	57
A step forward for Plasmodium falciparum malaria transmission-blocking vaccines	57
Learning and confirming in publicly funded antiviral trials	57
A shared history	57
A vanquished threat or a cautionary tale?	56
Experts react to SAGO's preliminary report	56
Monkeypox trial to begin in DR Congo	56
Deaths of unknown cause in DR Congo	55
Azithromycin mass drug administration: balancing survival benefits and risks in children	55
Antiblackness in the Ebola response in Sierra Leone	55
Lyda Osorio—tackling South America's infectious diseases	55
Reporting of deaths during cholera outbreaks: case fatality ratio and community deaths	55
COVID-19 versus influenza: the need to align policies with COVID-19 realities	55
Global measles cases up 20% in 2023	55
Sleeper frameworks for Pathogen X: surveillance, risk stratification, and the effectiveness and safety of therapeutic interventions	54
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden	54
Hospital admissions for group A streptococcal infections in England: current rates and historical perspective	54
Lessons from the English primary care sentinel network's response to the COVID-19 pandemic	54
Correction to Lancet Infect Dis 2025; 25: 764–74	53
Correction to Lancet Infect Dis 2023; 23: 789	53
Correction to Lancet Infect Dis 2025; 25: e11–12	53
Developing the EAVE III platform for future health crises	53
Correction to Lancet Infect Dis 2024; published online Feb 9. https://doi.org/10.1016/S1473-3099(23)00731-4	53
Mpox control strategies: using behaviour change to complement, not replace, vaccination	52
Successful use of interferon alfa-2a for persistent parvovirus B19 infection	52
Salmonella Typhimurium outbreak linked to chocolate	52
Candida albicans fungal ball in the eyeball	52
Humanitarian crisis in Tigray amidst civil war	52
Na-GST-1 adsorbed on Alhydrogel co-administered with different Toll-like receptor agonists in hookworm-naive adults using a controlled human infection model in the USA: a phase 2, double-blind, random	51
A new formulation of praziquantel to achieve schistosomiasis elimination	51
Revisiting oral antivirals for COVID-19 in the hospital setting	51
A new key-player for onchocerciasis elimination	51
Correction to Lancet Infect Dis 2025; published online Feb 13. https://doi.org/10.1016/S1473-3099(24)00749-7	50
H5N1 avian influenza: tracking outbreaks with real-time epidemiological data	50
Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prosp	50
What is the pandemic potential of avian influenza A(H5N1)?	50
Artificial intelligence to transform public health in Africa	49
Struggling with a new dengue epidemic in Nepal	49
Measuring population immunity against influenza using individual antibody titres: a multicountry, retrospective observational study	49
Disseminated Mycoplasma pneumoniae infection presenting with polyarthritis and endocarditis	49
Sense and susceptibility: predicting influenza dynamics from immune landscapes	49
Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021–22: a descriptive epidemiological study	48
Correction to Lancet Infect Dis 2025; published online Oct 29. https://doi.org/10.1016/S1473-3099(25)00466-9	48
Meningococcal disease, meningococcal vaccines, and the recent meningococcal outbreak in Kent, UK	47
Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation	46
Understanding vancomycin nephrotoxicity augmented by β-lactams: a synthesis of endosymbiosis, proximal renal tubule mitochondrial metabolism, and β-lactam chemistry	46
Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia	46
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomi	45
Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African c	44
Limited progress towards immunisation targets in 2023	44
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-base	44
The global alarm bell is ringing due to the threat of potential severe cases and deaths caused by clade I of monkeypox virus	44
A combined ELISA for infection-induced and vaccine-induced mpox antibodies during the clade Ib outbreak in Rwanda: an observational, cross-sectional, clinical validation study	44
Highlights from ASTMH 2024	44
Navigating treatment duration in osteoarticular Candida infections – Authors' reply	43
Mallika Imwong—championing malaria genomics	43
GLASS report on antibiotic use data for 2022	43
Infectious diseases in the COVID-19 era: gaps between countries	43
Ana Gligić	43
Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study	42
Correction to Lancet Infect Dis 2022; published online May 17. https://doi.org/10.1016/S1473-3099(22)00149-9	42
Ophthalmic manifestation of monkeypox infection	42
Correction to Lancet Infect Dis 2024; published online May 31. https://doi.org/10.1016/S1473-3099(24)00221-4	42
Spend wisely to eliminate malaria	42
Real-world use of nirmatrelvir–ritonavir: who benefits?	42
Multinational consensus antimicrobial stewardship recommendations for children managed in hospital settings	41
Determining force of infection for chikungunya to support vaccine policy development	41
The dignity of Indian female sex workers	41